NOVELTY – Composition comprises a poloxamer-based micellar system, 15-deoxy-delta-12,14-prostaglandin (PGJ2) as the active ingredient, and an aqueous carrier. USE – The composition is useful for treating and preventing acute or chronic inflammatory conditions of temporomandibular joint, arthritis or other conditions mediated by inflammatory intermediates (all claimed), and for reducing the inflammatory pain due to rheumatoid arthritis. Test details are described but no results given. ADVANTAGE – The composition: allows prolonged residence of PGJ2 at the site of injection and provides enhanced PGJ2 analgesic and antiinflammatory effect (claimed); delivers PGJ2 directly to the injured site, enabling the use of very small doses, with increased efficacy, reduced side effects, and allowing greater intervals between dosages.
B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B05 (Other organics – aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 – B05.)